CIK 0001314102 · Non-accelerated filer<br>Smaller reporting company
EyePoint, Inc.
Sign in to watch- Ticker
- EYPT
- Exchange
- Nasdaq
- Industry
- Laboratory Analytical Instruments
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 262774444
- Phone
- 617-926-5000
- Business address
- 480 PLEASANT STREET, SUITE C400, WATERTOWN, MA, 02472
- Former names
- EyePoint Pharmaceuticals, Inc., pSivida Corp., pSivida LTD
- Open-market buys, last 90 days
- $52,258
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$52,258. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-09 | Elston George Chief Financial Officer | Shares withheld for taxes | −1,458 | $28.80 | $42K | 43,607 |
| 2024-02-09 | Elston George Chief Financial Officer | Option exercise · Restricted Stock Units | −4,967 | 0 | ||
| 2024-02-09 | Elston George Chief Financial Officer | Option exercise · Restricted Stock Units | −5,833 | 5,834 | ||
| 2024-02-09 | Duker Jay S. President and CEO | Option exercise | +7,000 | 50,486 | ||
| 2024-02-09 | Duker Jay S. President and CEO | Option exercise | +4,967 | 55,453 | ||
| 2024-02-09 | Duker Jay S. President and CEO | Shares withheld for taxes | −2,075 | $28.80 | $60K | 53,378 |
| 2024-02-09 | Duker Jay S. President and CEO | Shares withheld for taxes | −1,458 | $28.80 | $42K | 51,920 |
| 2024-02-09 | Duker Jay S. President and CEO | Option exercise · Restricted Stock Units | −4,967 | 0 | ||
| 2024-02-09 | Duker Jay S. President and CEO | Option exercise · Restricted Stock Units | −7,000 | 7,000 | ||
| 2024-02-02 | Jones David Scott SVP & Chief Commercial Officer | Option exercise 10b5-1 | +209 | $11.47 | $2K | 38,171 |
| 2024-02-02 | Jones David Scott SVP & Chief Commercial Officer | Sale 10b5-1 | −209 | $28.49 | $6K | 37,962 |
| 2024-02-02 | Jones David Scott SVP & Chief Commercial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −209 | 4,375 | ||
| 2024-01-26 | Paggiarino Dario A. Chief Medical Officer | Option exercise 10b5-1 | +15,609 | $12.90 | $201K | 52,114 |
| 2024-01-26 | Paggiarino Dario A. Chief Medical Officer | Option exercise 10b5-1 | +51 | $13.13 | $670 | 52,165 |
| 2024-01-26 | Paggiarino Dario A. Chief Medical Officer | Option exercise 10b5-1 | +33,665 | $13.13 | $442K | 85,830 |
| 2024-01-26 | Paggiarino Dario A. Chief Medical Officer | Sale 10b5-1 | −51 | $25.41 | $1K | 85,779 |
| 2024-01-26 | Paggiarino Dario A. Chief Medical Officer | Sale 10b5-1 | −15,609 | $25.41 | $397K | 70,170 |
| 2024-01-26 | Paggiarino Dario A. Chief Medical Officer | Sale 10b5-1 | −33,665 | $25.77 | $868K | 36,505 |
| 2024-01-26 | Paggiarino Dario A. Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −51 | 51,253 | ||
| 2024-01-26 | Paggiarino Dario A. Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −33,665 | 17,588 |
Page 13 of 18 · 352 trades